January 2023 tender notification
Pharmac is pleased to provide the latest tender results
Download the tender notification [PDF 58 KB]
Tender results
Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2021/22 Invitation to Tender, dated 1 November 2021 and the 2022/23 Invitation to Tender, dated 31 October 2022.
Some of the pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. Pharmac will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:
- For new listings, by 4pm on 12 February 2023 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
Pharmac cannot list a product (and pharmacies cannot claim) without this information.
More information about this process and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link).
Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest).
Pharmac cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2021/22 Tender – Principal Supply Status applies until 30 June 2025
Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule
1. Tenders awarded to currently listed Pharmaceuticals where at least one other brand is listed
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand (Supplier) |
Date of listing |
Principal Supply Status date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
|
Hydrocortisone |
Crm 1%; 500 g tub |
$17.15 |
$20.40 |
Noumed |
1 March 2023 |
1 August 2023 |
PSM |
|
Pethidine hydrochloride |
Tab 50 mg; 10 tablet bottle pack |
$4.70 |
$8.68 |
Noumed Pethidine |
1 March 2023 |
1 August 2023 |
PSM |
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule
The decisions were as follows:
2. Tenders awarded to currently listed Pharmaceuticals where at least one other brand is listed
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
DV limit |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Hydrocortisone |
Crm 1%; 500 g tub |
$17.15 |
$20.40 |
Noumed |
5% |
1 March 2023 |
1 August 2023 |
PSM |
|
Pethidine hydrochloride |
Tab 50 mg; 10 tablet bottle pack |
$4.70 |
$8.68 |
Noumed Pethidine |
5% |
1 March 2023 |
1 August 2023 |
PSM |
2022/23 Tender – Principal Supply Status applies until 30 June 2026
Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule
3. Tenders awarded to currently listed Pharmaceuticals where no other brand is listed
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand |
Date of subsidy change |
Principal Supply date |
|---|---|---|---|---|---|---|
|
Cetirizine hydrochloride |
Tab 10 mg; 100 tablet blister pack |
$7.50 |
$1.71 |
Zista |
1 April 2023 |
1 September 2023 |
|
Flecainide acetate |
Cap long-acting 100 mg; 90 capsule blister pack |
$108.65 |
$35.78 |
Flecainide Controlled Release Teva |
1 March 2023 |
1 August 2023 |
|
Flecainide acetate |
Cap long-acting 200 mg; 90 capsule blister pack |
$167.92 |
$54.28 |
Flecainide Controlled Release Teva |
1 March 2023 |
1 August 2023 |
|
Roxithromycin |
Tab 150 mg; 50 tablet blister pack |
$29.50 |
$13.19 |
Arrow-Roxithromycin (Teva) |
1 March 2023 |
1 August 2023 |
|
Roxithromycin |
Tab 300 mg; 50 tablet blister pack |
$35.50 |
$25.00 |
Arrow-Roxithromycin (Teva) |
1 March 2023 |
1 August 2023 |
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule
4. Tenders awarded to Pharmaceuticals where no other brand is listed
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand |
DV |
Date of price change |
Principal Supply date |
|---|---|---|---|---|---|---|---|
|
Cetirizine hydrochloride |
Tab 10 mg; 100 tablet blister pack |
$7.50 |
$1.71 |
Zista |
5% |
1 April 2023 |
1 September 2023 |
|
Flecainide acetate |
Cap long-acting 100 mg; 90 capsule blister pack |
$108.65 |
$35.78 |
Flecainide Controlled Release Teva |
5% |
1 March 2023 |
1 August 2023 |
|
Flecainide acetate |
Cap long-acting 200 mg; 90 capsule blister pack |
$167.92 |
$54.28 |
Flecainide Controlled Release Teva |
5% |
1 March 2023 |
1 August 2023 |
|
Roxithromycin |
Tab 150 mg; 50 tablet blister pack |
$29.50 |
$13.19 |
Arrow-Roxithromycin (Teva) |
5% |
1 March 2023 |
1 August 2023 |
|
Roxithromycin |
Tab 300 mg; 50 tablet blister pack |
$35.50 |
$25.00 |
Arrow-Roxithromycin (Teva) |
5% |
1 March 2023 |
1 August 2023 |
For products included in the 2020/21, 2021/22 or 2022/23 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.